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OBJECTIVE — We evaluated associations of serum retinol-binding protein 4 (RBP4) with
subclinical cardiovascular disease (CVD).
RESEARCH DESIGN AND METHODS — Subclinical CVD was measured with echo-
cardiography, carotid artery ultrasound, brachial artery ultrasound, and invasive forearm endo-
thelial vasoreactivity in 1,008 70-year-old participants (50% women) of the Prospective
Investigation of the Vasculature in Uppsala Seniors (PIVUS) study.
RESULTS — In analyses adjusted for multiple CVD risk factors, we observed inverse associ-
ationsofRBP4withcarotidarteryintima-media(0.39,95%CI0.55to0.22)andplaque
( 0.33, 95% CI 0.60 to 0.05) echogenicity (gray scale median).
CONCLUSIONS — Circulating RBP4 concentrations were inversely associated with intima-
media and plaque echogenicity in carotid arteries. These ﬁndings imply that RBP4 could be
involved in the development of atherosclerosis.
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R
etinol-binding protein 4 (RBP4) is el-
evated in individuals with insulin re-
sistance and type 2 diabetes (1).
RecentobservationsthatserumRBP4corre-
lates with subclinical inﬂammation early in
obesity development (2) and that RBP4
mRNA expression in adipose tissue is re-
latedtoinﬂammationratherthaninsulinre-
sistance (3) have prompted the hypothesis
that RBP4 may elicit subclinical inﬂamma-
tion leading to cardiovascular disease
(CVD). We hypothesized that RBP4 would
be associated with atherosclerosis, left ven-
tricular geometry and function, and/or en-
dothelial function—intermediate
phenotypesonpathwaysfrominsulinresis-
tance and subclinical inﬂammation to clin-
ical CVD—and that these associations
would be modiﬁed by type 2 diabetes.
RESEARCH DESIGN AND
METHODS— The Prospective Inves-
tigation of the Vasculature in Uppsala Se-
niors (PIVUS) study has been described
elsewhere (4) (http://www.medsci.uu.se/
pivus/pivus.htm). Brieﬂy, 1,016 free-liv-
ing 70-year-old individuals from Uppsala
County attended the baseline examina-
tion. The present study sample consisted
of 1,008 participants with valid RBP4
measurements. The study was approved
by the Uppsala University Ethics Commit-
tee, and participants gave written informed
consent.
RBP4 was assayed using a commer-
cially available ELISA kit (Phoenix Eu-
rope, Karlsruhe, Germany). The average
intra- and interassay CVs were 4.6 and
9.8%. A comprehensive two-dimensional
and Doppler echocardiography was per-
formed;measurementsincludedleftatrial
diameter, interventricular septal thick-
ness (IVS), left ventricular posterior wall
thickness (PW), ejection fraction, and left
ventricular diameter in end diastole
(LVEDD). Left ventricular wall thickness
was calculated as IVS  PW, and left
ventricular mass as 0.8 [1.04(IVS 
LVEDDPW)
3(LVEDD
3)0.6g](5).
The carotid artery was assessed by exter-
nal B-mode ultrasonography. Intima-
media thickness (IMT) was evaluated in
the far wall in the common carotid artery,
1–2 cm proximal to the bulb. No overt
plaques were included in the IMT mea-
surement. The images were digitized, and
gray scale median (GSM) in IMT (GSM-
IM) and plaques were performed using
semiautomated methods. Common ca-
rotid artery distensibility was calculated
as the percentage change in the diameter
divided by the central pulse pressure
obtained by pulse-wave analysis. Endo-
thelium-dependent vasodilation was
evaluated with brachial artery B-mode
ultrasound (ﬂow-mediated vasodila-
tion) and invasive forearm technique
with intrabrachial infusion of acetyl-
choline (endothelium-dependent vaso-
dilation). Endothelium-independent
vasodilation was evaluated with inva-
sive forearm technique with infusion of
sodium nitroprusside.
Age- and sex-adjusted and multivari-
able-adjusted (adjusted for age, sex, BMI,
systolic blood pressure, antihypertensive
medication, log plasma glucose, antidia-
betes medication, total cholesterol, HDL
cholesterol, creatinine, current/former
smoking, and physical activity) linear re-
gressions were used to relate RBP4 con-
centrations to subclinical CVD. In
conﬁrmatory analyses, we used multiple
imputation methods to impute missing
data. Multiple testing corrections were
performed by calculation of empirical P
values using bootstrap methods. Statisti-
cal software package Stata 10.1 (Stata,
College Station, TX) was used.
RESULTS— Characterization of sub-
clinical CVD in our sample and associa-
tions of RBP4 with subclinical CVD are
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adjusted analyses, RBP4 was inversely as-
sociated with IM-GSM and plaque GSM
(corrected for multiple testing, P 
0.0001 and 0.056). Creatinine was found
tobeastrongnegativeconfounderofboth
of these associations and to be an effect
modiﬁer in the relation of RBP4 to IM-
GSM ( 0.44, P  0.0001, and 
0.08, P  0.65, in individuals with cre-
atinine below or above the 75th percen-
tile; P for interaction  0.004).
ThemeanconcentrationsofRBP4did
not differ between men and women (31.2
vs. 30.9 g/ml, P  0.50). There were no
sex differences regarding associations of
RBP4 with IM-GSM, and there was no ev-
idence that type 2 diabetes (n  118,
12%) acted as an effect modiﬁer of the
relation of RBP4 with IM-GSM or
plaque GSM.
In secondary analyses including total
energy intake by 7-day registration and
useofhormonereplacementtherapy(n
229) in the multivariable models, the re-
sults were unchanged. In conﬁrmatory
analysesusingmultipleimputationmeth-
ods, we obtained essentially the same re-
sults.Inaposthocpoweranalysis,wehad
82% or higher statistical power to detect
an increment to the model R
2 of 0.0125
(at 0.05) for all subclinical CVD
measures.
CONCLUSIONS— Several lines of
evidencesupportapotentialroleforRBP4
in pathways linking adiposity with ath-
erosclerosis. Serum RBP4 levels are in-
creased and correlate with subclinical
inﬂammation in childhood obesity (2),
and RBP4 mRNA expression in adipose
tissue is associated with inﬂammatory
markers (3). RBP4 concentrations are as-
sociated with pro-atherogenic VLDL cho-
lesterol and triglycerides in patients with
type 2 diabetes or coronary artery disease
(6). Also, RBP4 was associated with inci-
dent coronary artery disease in a recent
nested case-control study (7).
WereportthatRBP4wasinverselyas-
sociated with intima-media and plaque
GSM in the carotid arteries of individuals
with normal kidney function. GSM is a
measureofechogenicityofthevesselwall;
a lower value corresponds to a darker ul-
trasound image, i.e., a higher fat content
(8). IM-GSM and plaque GSM are highly
correlated (8), and plaque echogenicity is
an independent risk factor for ischemic
cerebrovascular disease (9). Our ﬁnding
that higher RBP4 is associated with a
higherfatcontentinthevesselwallandin
atherosclerotic plaques might reﬂect the
known lipid-modulating activities of reti-
noids and retinol-binding proteins, such
as expression of several genes involved in
triglyceride metabolism, including regu-
lators of ApoC-III production, hepatic
andintestinaltriglycerideproductionand
secretion, and -oxidation (10).
There were some limitations of our
Table 1—Associations of serum RBP4 with measures of subclinical CVD (N  1,008)*
n
Age- and sex-adjusted Multivariable-adjusted
Mean  SD  (95% CI) Nominal P  (95% CI) Nominal P
Echocardiographic measures
LV mass (g) 916 181  60 0.28 (0.13 to 0.69) 0.19 0.12 (0.47 to 0.23) 0.50
LV wall thickness (mm) 916 21  4 0.03 (0.01–0.06) 0.016 0.00 (0.03 to 0.02) 0.76
LV end-diastolic diameter (mm) 918 47  6 0.00 (0.04 to 0.03) 0.80 0.01 (0.05 to 0.03) 0.62
Ejection fraction (%) 830 67  8 0.01 (0.06 to 0.07) 0.85 0.01 (0.05 to 0.08) 0.70
LV isovolumic relaxation time (ms) 888 121  21 0.10 (0.05 to 0.25) 0.20 0.05 (0.20 to 0.10) 0.50
Left atrial diameter (mm) 946 39  7 0.00 (0.05 to 0.05) 0.98 0.02 (0.07 to 0.02) 0.30
log E/A ratio 932 0.97  0.28 0.00 (0.00–0.00) 0.85 0.00 (0.00–0.00) 0.94
Carotid ultrasound measures
IMT (mm) 947 0.89  0.16 0.00 (0.00–0.00) 0.34 0.00 (0.00–0.00) 0.12
IM-GSM 983 79  24 0.21 (0.37 to 0.05) 0.011 0.39 (0.55 to 0.22) 0.0001
Number of carotid arteries with
plaques† 936 0.00 (0.00–0.01) 0.59 0.00 (0.00–0.01) 0.94
0 324  35
1 340  36
2 272  29
Plaque GSM‡ 589 74  32 0.17 (0.43 to 0.08) 0.19 0.33 (0.60 to 0.05) 0.020
Measures of arterial compliance
logCCA distensibility (%) 872 2.5  0.5 0.00 (0.01 to 0.00) 0.30 0.00 (0.00–0.00) 0.26
Endothelial function measures
FMD (%) 982 4.8  3.6 0.01 (0.01 to 0.04) 0.28 0.01 (0.02 to 0.04) 0.49
logEDV (%) 859 524  311 0.00 (0.01 to 0.00) 0.19 0.00 (0.00–0.00) 0.79
logEIDV (%) 876 369  213 0.00 (0.00–0.00) 0.62 0.00 (0.00–0.00) 0.85
RBP4 (g/ml) 1,008 31.1  9.1 NA NA NA NA
*Data from models with measures of subclinical disease as dependent variables and RBP4 with age and sex (in age- and sex-adjusted analyses) or age, sex, BMI,
systolic blood pressure, antihypertensive medication, log plasma glucose, antidiabetes medication, total cholesterol, HDL cholesterol, creatinine, current or former
smoking, and physical activity (in multivariable-adjusted analyses) as independent variables. -coefﬁcients are for a 1-unit increase of RBP4 and represent a change
of subclinical measures in natural units (or log natural units for E/A ratio, common carotid artery distensibility, endothelium-dependent vasodilation, and
endothelium-independent vasodilation). †Data represent n (%) of individuals with 0, 1, or 2 carotid arteries with plaques and the -coefﬁcient per additional artery
withaplaque.‡LowestGSMinaplaqueateitherside,exceptforwhentheGrey-Wealscaleateithersidewas4,inwhichcasethehighestplaqueGSMwasrecorded.
CCA, common carotid artery; EDV, endothelium-dependent vasodilation; EIDV, endothelium-independent vasodilation; FMD, ﬂow-mediated dilation; LV, left
ventricular; NA, not applicable.
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consisted of elderly men and women of
Europeanethnicity,thegeneralizabilityto
other age-groups and ethnicities is un-
known. Second, even though we cor-
rected for multiple testing, our results
could represent false-positive ﬁndings
and should be considered hypothesis
generating. Third, because our study was
cross-sectional, we cannot assess causal-
ity or longitudinal tracking of subclinical
CVD. Fourth, even though RBP4 re-
mainedsigniﬁcantlyassociatedwithGSM
in multivariable models adjusting for po-
tentialconfounders,wecannotruleoutthe
possibility of some residual confounding or
confounding by unmeasured factors.
In our community-based sample, cir-
culating RBP4 concentrations were associ-
ated with intima-media and plaque
echogenicity in carotid arteries in individu-
als with normal kidney function. These
ﬁndingsimplythatRBP4couldbeinvolved
in the development of atherosclerosis. We
didnotﬁndaneffect-modifyingroleoftype
2 diabetes in the associations. Further
studies are needed to validate and evalu-
ate clinical implications of our ﬁndings.
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